PT  - JOURNAL ARTICLE
AU  - F.E. Valles
AU  - C.L. Perez-Valles
AU  - S. Regalado
AU  - R.F. Barajas
AU  - J.L. Rubenstein
AU  - S. Cha
TI  - Combined Diffusion and Perfusion MR Imaging as Biomarkers of Prognosis in Immunocompetent Patients with Primary Central Nervous System Lymphoma
AID  - 10.3174/ajnr.A3165
DP  - 2012 Aug 30
TA  - American Journal of Neuroradiology
4099  - http://www.ajnr.org/content/early/2012/08/23/ajnr.A3165.short
4100  - http://www.ajnr.org/content/early/2012/08/23/ajnr.A3165.full
AB  - BACKGROUND AND PURPOSE: ADC derived from DWI has been shown to correlate with PFS and OS in immunocompetent patients with PCNSL. The purpose of our study was to confirm the validity of ADC measurements as a prognostic biomarker and to determine whether rCBV measurements derived from DSC perfusion MR imaging provide prognostic information. MATERIALS AND METHODS: Pretherapy baseline DWI and DSC perfusion MR imaging in 25 patients with PCNSL was analyzed before methotrexate-based induction chemotherapy. Contrast-enhancing tumor was segmented and coregistered with ADC and rCBV maps, and mean and minimum values were measured. Patients were separated into high or low ADC groups on the basis of previously published threshold values of ADCmin < 384 × 10−6 mm2/s. High and low rCBV groups were defined on the basis of receiver operating curve analysis. High and low ADC and rCBV groups were analyzed independently and in combination. Multivariate Cox survival analysis was performed. RESULTS: Patients with ADCmin values < 384 × 10−6 mm2/s or rCBVmean values < 1.43 had worse PFS and OS. The patient cohort with combined low ADCmin–low rCBVmean had the worst prognosis. No other variables besides ADC and rCBV significantly affected survival. CONCLUSIONS: Our study reinforces the validity of ADC values as a prognostic biomarker and provides the first evidence of low tumor rCBV as a novel risk factor for adverse prognosis in immunocompetent patients with PCNSL. Abbreviations CELcontrast-enhancing lesionDSCdynamic susceptibility-weighted contrast-enhancedminminimumOSoverall survivalPCNSLprimary central nervous system lymphomaPFSprogression-free survivalrCBVrelative cerebral blood volume